FDA Play: Soligenix, Poised for a Stellar Comeback (OTC:SNGX.OB)
The past year and a half has come to be known as the rise of the small cap biotechs — Anyone wants to contact a famous producer for a movie suggestion? Terminator: Rise of the Machines, oh please. Nothing seems to stand in the way of these once forgotten ghosts, as they are now appearing as front page news on just about every large major financial news portal. Welcome to Soligenix Inc., a company that has such a vast potential. First stumbling upon this company, it felt like it was Christmas over and over again. Investors have grown weary of the same old story: Phase III results, deep pipeline, government grants for one or two million, comparisons to other more successful companies, the list goes on and on. So why Soligenix? Simple, it simply tears through the potential of practically every other company StocksHaven has profiled. Don’t expect this market cap of 56.92M to last much longer.
And the horses are off, starting out of the gates with patents, follow that up with eight treatments/vaccines in the pipeline, their main drug (orBec) which has received Orphan Drug status and been under phase III with a market potential of $300M annually, take a lead from the pack with a presentation from the President and CEO at the Rodman & Renshaw, $3.85M financing from partners and institutional investors, go on for more institutional investors, $9.4M NIH grant, there are more grants but lets leave that to the profile, potential $30M North American partnership, positive clinical trials plastered all over the latest press releases, orphan drug status obtained on their main phase III drug – There are so many things going on with this company, it will literally make anyone’s head spin by the finish line. We can practically go on and on about the positives of this company, however, let’s finally get to the company profile. And so, the story begins… oops we meant novel.
About Soligenix, Inc.
Soligenix, Inc., formerly DOR Biopharma, Inc., research and development biopharmaceutical company focused on developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases where there remains an unmet medical need; as well as several biodefense vaccines. The Company maintain two active business segments: BioTherapeutics and BioDefense. During the year ended December 31, 2008, the Company had two customers, the United States Federal Government and Orphan Australia Pty Ltd. (Orphan Australia), a specialty pharmaceutical company based in Melbourne, Australia. The Company’s biodefense business segment intends to convert its ricin toxin, botulinum toxin, and anthrax vaccine programs from early stage development to advanced development and manufacturing.
The company is primarely a late-stage biopharmaceutical company committed to the development of life-saving therapeutics and vaccines. Soligenix has two areas of focus: 1) a therapeutics platform dedicated to the development of products for life-threatening conditions such as gastrointestinal Graft-versus-Host disease and cancer, and 2) a biodefense platform to develop vaccines for military and civilian applications.
The full special report on the company appears today at http://www.stockshaven.com/fda-play-soligenix-poised-for-a-stellar-comeback-otcsngx-ob/
Disclosure: Short-term position in SNGX
About StocksHaven Investments
StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.
For more financial and investment news, visit www.StocksHaven.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- Michael Vlaicu
- Founder and Lead Investment Analyst
- StocksHaven Investments
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.